The trial, which involved more than 8,000 adults 50 and older, found that antibody levels generated by the new vaccine were about 20% to 40% higher than getting the shots apart, with the exception of ...

Stat: Vinay Prasad's FDA Speech: Praises Staff, Embraces Evidence In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his admiration for agency ...

Therapies involving mRNA, a key to Covid vaccines, hold great potential in treating several diseases, but some lawmakers want ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

In a study published in the Journal of the American Medical Association, researchers from Moderna reported that the new combo ...

Moderna’s study, involving 8,000 adults 50 and older, showed the new combo shot generated an immune response against COVID and most strains of flu compared to existing stand-alone shots.

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the ...

MM+M Women of Distinction honoree, announced Monday morning that she has joined Medtronic Diabetes as its chief marketing ...

The Novavax vaccine is the only COVID-19 booster ... A decision on full approval – which rival mRNA shots from Moderna and Pfizer and its partner BioNTech already have - was due from the Food ...

vaccine technology. The contested patent covers “modified nucleosides, nucleotides, and nucleic acids and their uses” — a foundational component in mRNA-based therapeutics. Moderna’s use ...

Moderna's patent is being used as a key technology for the manufacture of several mRNA pharmaceuticals, including the Japanese encephalitis vaccine candidate 'GBP560' that SK bioscience is developing.